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Cardiac amyloidosis, a disease caused by the precipitation of amyloid proteins in
the myocardial extracellular matrix has been historically difficult to diagnose due
to lack of specific clinical manifestations and necessity of biopsy to demonstrate
amyloid deposition. However, advances in cardiovascular imaging techniques
have facilitated earlier recognition of this disease. In addition, while once thought
of as incurable, treatment strategies are emerging for cardiac amyloidosis,
making early diagnosis essential.
CASE SUMMARY
We outline the case of a 73 years old African American female who was admitted
with sudden onset shortness of breath and found to be in cardiogenic shock.
Cardiac amyloidosis was suspected due to discordance between
electrocardiogram and echocardiogram findings and this was subsequently
confirmed with the aid of scintigraphy and an endomyocardial biopsy.
CONCLUSION
Our objective is to highlight the diagnostic evaluation and clinical implications of
cardiac amyloidosis.
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Core tip: Modern cardiovascular imaging techniques have facilitated earlier identification
of cardiac amyloidosis, an important but under diagnosed cause of restrictive
cardiomyopathy and heart failure. Early diagnosis is key as treatment strategies are
emerging which have the potential to alter the disease course.
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With an increasingly ageing population and advances in cardiovascular imaging
techniques,  conditions  that  previously  went  undiagnosed  and  thought  to  be
uncommon are being increasingly identified.  Cardiac amyloidosis is  one of such
conditions.  In  addition,  with  broad  research  ongoing  on  various  modalities  of
treatment, early diagnosis may be crucial to limiting further amyloid deposition and
thus, alter the disease course. In this case report, we discuss a 73 years old female
admitted in cardiogenic shock with subsequent workup confirming a diagnosis of
cardiac  amyloidosis.  A  review  of  the  condition  focusing  on  the  diagnosis  and
treatment is also included.
CASE PRESENTATION
Chief complaints
A 73 years old African American female presented to the emergency department with
sudden onset shortness of breath with no associated chest pain. She was emergently
intubated due to impending respiratory failure.
History of present illness
Her  medical  history  was  notable  for  congestive  heart  failure,  atrial  fibrillation,
primary hyperparathyroidism, carpal tunnel syndrome and spinal stenosis.
History of past illness
She had a longstanding history of heart failure first diagnosed in January 2010 with
echocardiogram (ECHO) demonstrating a left ventricular ejection fraction (LVEF) of
40%. A cardiac catheterization in February 2014 revealed non-obstructive coronary
artery disease; hence, the cardiomyopathy was labelled non-ischemic. Due to non-
recovery of systolic function and persistent left bundle branch block (LBBB), she had a
biventricular cardioverter-defibrillator (ICD) implanted in March 2014.
Medication History
Her pre  admission medications  included apixaban 5  mg twice  a  day,  sacubitril-
valsartan (24-26 mg) twice a day, furosemide 20 mg twice a day, metoprolol succinate
25 mg daily and sotalol 80 mg twice a day.
Physical examination upon admission
On initial physical examination, she had a blood pressure of 80/54 mmHg with pulse
rate of 75 beats per minute (bpm). Her jugular venous pressure was not elevated. She
had clear lungs and normal heart sounds with no murmurs or gallops on auscultation.
Her lower extremities were cool to touch with mild pitting edema bilaterally.
Laboratory examinations
Laboratory testing was significant for N-terminal pro b-type natriuretic peptide (NT-
ProBNP) elevation at 12914 pg/mL (Normal < 125 pg/mL). Complete blood count
and comprehensive metabolic panel were within normal limits.
Serum protein electrophoresis obtained to evaluate for an underlying gammopathy
(seen  in  light  chain  amyloidosis)  demonstrated  moderate  hypoproteinemia  and
hypoalbuminemia with no monoclonal spike (M spike).  The serum free kappa to
lambda light chain ratio was within normal limits and urine immunofixation was
negative for immunoglobulin light chain ruling out a gammopathy.
Imaging examinations
Electrocardiogram (ECG) showed LBBB and low voltages in the limb leads (Figure 1)
while the chest radiograph demonstrated bilateral patchy opacities consistent with
pulmonary edema.
Transthoracic ECHO revealed a borderline dilated left ventricle (LV) with severe
left ventricular hypertrophy and reduced LVEF of 30%-35% (Figures 2-6).
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Figure 1
Figure 1  Electrocardiogram – Left bundle branch block with low voltage in limb leads.
Due to the discordance between the degree of LV thickness on ECHO and QRS
voltage on ECG, cardiac amyloidosis was considered as a possible etiology of the
cardiomyopathy.
Cardiovascular magnetic resonance imaging (MRI) could not be obtained as her
ICD was not MRI compatible.  A 99Technetium pyrophosphate (99mTc-PYP) planar
scintigraphy  was  subsequently  done  (Figure  7).  Quantitative  analysis  of  heart
retention  patterns  showed  a  heart  to  contralateral  (H/Cl)  ratio  of  1.8,  strongly
suggestive of transthyretin amyloid deposition. An abdominal fat pad biopsy was
also done which had no evidence of amyloid deposition on pathologic examination.
Medical management
A pulmonary  artery  catheter  was  placed  on  admission  which  showed a  central
venous pressure of 3 mmHg with cardiac output (CO) of 2.06 L/min and cardiac
index of 1.12 L/min/m2. An assessment of cardiogenic shock was made and inotrope
therapy with intravenous dobutamine was initiated.
With improvement in her hemodynamic status, she was able to be weaned off the
inotrope support and was eventually extubated. Her hospital course was complicated
by multiple episodes of flash pulmonary edema. This was attributed to the narrow
window between high and low filling pressures which made accurate assessment of
fluid status and diuretic requirements tedious. She progressed well with addition of
isosorbide dinitrate/hydralazine (40-75 mg) twice a day to her medication regimen
prior to discharge home.
Post  discharge,  an  endomyocardial  biopsy  was  done  which  confirmed
Transthyretin Amyloidosis – wild type.
FINAL DIAGNOSIS
Wild type transthyretin cardiac amyloidosis.
TREATMENT
The main aim of treatment following diagnosis was optimizing her cardiac function
and managing symptoms as there is no approved therapy for transthyretin cardiac
amyloidosis currently. Neurohormonal blocking agents for her systolic dysfunction
were continued with titration of her diuretic depending on her volume status. In the
future, she may be a good candidate for one of the amyloid specific therapies under
investigation.
OUTCOME AND FOLLOW-UP
She has been enrolled in an amyloid program and has required regular clinic follow
up since diagnosis. She has remained stable.
DISCUSSION
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Figure 2
Figure 2  Parasternal long axis echocardiographic view demonstrating severe concentric left ventricular
hypertrophy with small pericardial effusion.
Amyloidosis is a systemic disorder characterized pathologically by the extracellular
deposition of insoluble fibrils composed of misfolded proteins in various organs
including the heart with resulting alteration in structure and function[1]. The amyloid
fibrils are rigid, proteolytic resistant structures, typically less than 10 nanometers in
diameter with a characteristic apple-green birefringence with Congo-red staining
under polarized light microscopy[2].
Amyloidosis may be hereditary or acquired and the nature of the precursor protein
of the fibrils forms the basis of classification[3]. More than 30 such precursor proteins
have been identified and of these, 2 types are responsible for about 95% of cases of
cardiac amyloidosis: Immunoglobulin light chain amyloidosis (AL) and transthyretin
amyloidosis (ATTR)[4].
AL, although overall a rare condition, is the most frequently diagnosed form with
about 0.3 cases per 100000 population in a large referral center[5]. AL occurs secondary
to a plasma cell dyscrasia resulting in excessive production of immunoglobulin light
chain units,  with associated misfolding and deposition in extracellular tissue.  In
addition to cardiac manifestations, hepatic, renal and neurologic complications may
be seen in AL. Early diagnosis and initiation of treatment in AL may alter disease
outcome although mortality remains high[6].
ATTR  occurs  due  to  the  misfolding  of  the  liver  derived  precursor  protein
transthyretin (TTR, previously called prealbumin). TTR has a tendency to dissociate
into dimers and monomers and subsequently aggregate into insoluble fibrils[7,8]. Two
variants of this form of amyloidosis have been described – the hereditary/mutant
form caused by mutations in the TTR  gene and the sporadic/wild type (systemic
senile amyloidosis)[9].
The phenotype of mutant ATTR is dependent on the nature of the underlying
mutation with over 100 different mutations known to involve the TTR gene. The
Val30Met  (Valine  to  Methionine  at  position  30)  mutation  is  the  most  common
worldwide[7].  Of particular significance from a cardiac standpoint is the Val122Ile
(Valine  to  Isoleucine  at  position  122)  mutation  which  has  been  identified  in  a
significant percentage of the North American black population and is associated with
an increased risk of cardiac manifestations.  Neurologic symptoms in the form of
peripheral/autonomic neuropathy are the dominant presentation of mutant ATTR.
Wild type ATTR was previously described to be exclusive to older white males.
However, more cases in females are being identified as in our patient suggesting this
condition may underdiagnosed in this population[2,7]. Initial manifestations of wild
type ATTR may include carpal tunnel syndrome (especially bilateral)  and spinal
stenosis and these may precede the cardiac complications by several years.
Pathology/pathophysiology
The diffuse deposition of amyloid fibrils in the cardiac interstitial space produces
significant thickening of both ventricles with associated stiffness which results in
impaired diastolic relaxation and the characteristic restrictive physiology[2,9]. Fibril
deposition within and/or around the smaller  vessels  of  the heart  with resulting
narrowing may produce ischemia/infarction[10]. In addition, there is evidence pointing
to the direct toxicity of the fibrils to the cardiac myocytes especially with AL[9,11]. The
atria, valves and conduction system are also typically involved resulting in sequelae
such as atrial fibrillation, valvular regurgitation and various degrees of heart block.
Clinical manifestations
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Figure 3
Figure 3  Short axis echocardiographic view demonstrating severe concentric left ventricular hypertrophy
with small pericardial effusion.
The  classic  clinical  presentation  of  cardiac  amyloidosis  is  with  symptoms  of
congestive heart failure including exertional dyspnea and orthopnea. Fatigue and
weakness are also common, resulting from compromised CO. Symptoms of right
ventricular failure including abdominal distension and lower extremity edema may
be more prominent in certain patients[2,12].
Coronary vessel involvement may manifest with angina while palpitations and
syncope may be seen with the various conduction abnormalities associated with this
condition, atrial fibrillation being the most commonly identified arrhythmia[2,12].
Pericardial  and  pleural  effusions  may  be  seen  with  more  advanced  cardiac
dysfunction.  A  great  variety  of  extra-cardiac  symptoms/signs  may  be  seen  in
amyloidosis including ecchymoses/petechiae,  hepatomegaly,  macroglossia,  non-
specific gastrointestinal symptoms such as diarrhea/weight loss and carpal tunnel
syndrome (especially bilateral which is common in ATTR)[13,14].
Clinical evaluation
Diagnosing cardiac amyloidosis requires a high index of suspicion due to its relatively
low incidence. Typically, a combination of laboratory tests, ECG, cardiac imaging and
histopathology is required.
Plasma levels of the natriuretic peptides (BNP and NT-proBNP) tend to be high in
cardiac amyloidosis irrespective of severity of heart failure. This likely reflects the
direct toxicity of the amyloid fibrils at a cellular level as alluded to previously[15].
Measuring the level of NT-proBNP however has some prognostic value with its use in
the Mayo staging system for AL.
Serum levels of troponin T and/or troponin I are frequently chronically elevated in
CA. This may reflect small vessel ischemia or direct myocyte toxicity[2]. Takashio et
al[16]  however  demonstrated  the  utility  of  high  sensitivity  cardiac  troponin  T  in
differentiating cardiac amyloidosis from other cardiac conditions with a hypertrophic
phenotype.
Assaying circulating levels of TTR has limited clinical utility in evaluating for
ATTR. Work up for a monoclonal  process to evaluate for AL is  however always
indicated when cardiac amyloidosis is suspected. The preferred test for this is the
serum free light chain assay with immunofixation (as against the traditional serum
and urine protein electrophoresis which are not sufficiently sensitive)[2]. An abnormal
kappa to lambda ratio (< 0.26 or > 1.65) in combination with a M protein spike on
immunofixation is  highly suggestive  of  a  monoclonal  light  chain process[2].  It  is
important to note that identifying an abnormal plasma cell clone alone is insufficient
for diagnosis as a moderate increase in circulating light chains in not necessarily
pathologic.
The first clue which may prompt suspicion for cardiac amyloidosis is the ECG. The
archetypal finding is low QRS voltages due to the electrically silent amyloid fibrils
which  are  not  detected  by  the  ECG[2,12].  This  is  inconsistent  with  the  degree  of
ventricular thickening seen on ECHO. The absence of  low QRS voltage does not
preclude a diagnosis of cardiac amyloidosis with only 30%-70% of patients meeting
low voltage criteria on ECG[17,18]. A pseudoinfarct pattern with Q waves in the early
precordial leads is another common ECG finding, identified in about 40%-50% of CA
patients[19,20]. Other ECG findings frequently encountered include atrial arrhythmias
such as atrial fibrillation, various degrees of atrioventricular block, interventricular
conduction delays and bundle branch blocks.
The ECHO findings in cardiac amyloidosis are nonspecific but highly suggestive in
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Figure 4
Figure 4  Four chamber echocardiographic view demonstrating bi atrial enlargement, left ventricular
hypertrophy, small pericardial effusion and implantable cardioverter-defibrillator device.
the  right  clinical  context.  The  hallmark  finding  is  symmetric  biventricular  wall
thickening  with  a  spectrum  of  diastolic  abnormalities  varying  from  abnormal
relaxation to a restrictive filling pattern[2,9,21]. Cardiac amyloidosis should be suspected
with LV wall thickness greater than 12 mm in the absence of preceding history of
hypertension[2]. Atrial dilation is commonly seen due to the combination of deposition
of fibrils in the atria and elevated LV filling pressures. Thickening of the heart valves
is  also  commonplace  which  helps  to  distinguish  cardiac  amyloidosis  from
hypertensive heart disease[2]. LVEF typically remains preserved until later in disease
course when the effects of myocyte necrosis and fibrosis affect systolic function[21]. An
apical sparing pattern of strain on 2D speckle ECHO has been described by several
authors as being specific for cardiac amyloidosis enabling differentiation from other
cardiac diseases with a hypertrophic phenotype[2,21]. The pattern of strain is due to a
decrease in longitudinal strain in the basal and mid wall regions in comparison to the
apex  where  the  strain  is  relatively  preserved[12].  Small  pericardial  effusions  are
common and nonspecific. Larger effusions and cardiac tamponade are relatively rare.
Cardiac MRI has taken on an increasingly important role in the screening and
evaluation  of  cardiac  amyloidosis.  The  typical  finding  is  a  transmural  or
subendocardial pattern of late gadolinium enhancement (LGE). Global involvement is
more commonly encountered although a focal patchy pattern may be seen. These
features may precede the morphologic phenotype of increased LV wall thickness[22-24].
In AL cardiac amyloidosis, the global pattern of LGE has been shown to be predictive
of mortality and provides prognostic information beyond the clinical and biochemical
data used in the Mayo staging[25]. The main constraint to use of this imaging modality
is the inability to administer gadolinium contrast to patients with significant kidney
disease.
Nuclear scintigraphy with the use of bone seeking, phosphate-based radiotracers
including  99mTc-PYP  and  99mTc-DPD  (technetium-3,3-diphosphono-1,2-pro-
panodicarboxylic  acid)  has  demonstrated excellent  sensitivity  and specificity  in
diagnosing cardiac amyloidosis and differentiating ATTR from AL[26,27]. Only 99mTc-
PYP is currently approved for use in the United States but similar results have been
demonstrated  with  99mTc-DPD  in  European  studies.  The  exact  mechanism  for
accumulation  of  the  radiotracers  in  ATTR  cardiac  amyloidosis  is  unclear.  It  is
hypothesized that this may be related to higher calcium levels in ATTR which results
in more intense binding with the radiotracers[26]. By comparing the heart retention
patterns with the contralateral chest wall, a heart to contralateral ratio is obtained. A
heart to contralateral ratio greater than 1.5 is strongly suggestive of ATTR cardiac
amyloidosis.
There  has  been  recent  increased  interest  in  the  role  of  positron  emission
tomography/computerized  tomography  (PET/CT)  in  the  imaging  of  cardiac
amyloidosis. PET tracers, fluoride labelled radioisotopes including 18F-florbetapir and
18F-florbetapen,  have  been  demonstrated  to  bind  at  sites  of  amyloid  deposition
irrespective of the nature of the precursor protein[28].  The potential  utility of this
imaging modality has been evaluated in a few small single center studies.  Using
parameters including the standard uptake value and retention index, subjects with
both ATTR and AL cardiac amyloidosis were accurately identified over controls and
the burden of amyloid deposition could be quantified[29,30]. Larger, multicenter studies
are required to evaluate the clinical utility of this modality.
Despite these advances in cardiovascular imaging, histopathologic confirmation of
amyloid deposits in tissue remains the gold standard. In addition to confirming the
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Figure 5
Figure 5  Doppler demonstrating restrictive physiology with medial E’ velocity of 2.78 cm/s and E/Med E’ 39.2.
diagnosis,  it  also allows identification of  the specific  precursor  protein which is
important for guiding therapy[4]. Tissue may be obtained from extra-cardiac sites such
as  the abdominal  fat  pad and rectum by fine  needle  aspiration and apple  green
birefringence under polarized light microscopy after Congo-red staining is diagnostic.
Although immunohistochemical techniques may be used, liquid chromatography-
tandem mass spectrometry on samples obtained by laser microdissection is a more
sensitive and specific test for identifying the specific amyloid protein[4]. A negative
biopsy  from an  extra  cardiac  site  does  not  rule  out  cardiac  amyloidosis  and an
endomyocardial biopsy should be obtained in such cases. This procedure is however
limited  to  larger  referral  centers  and  carries  the  small  but  significant  risk  of
ventricular perforation.
Treatment
The treatment of cardiac amyloidosis is two pronged – treatment of symptoms arising
from cardiac dysfunction and treatment of the underlying amyloidosis. The most
commonly encountered manifestations of cardiac amyloidosis are congestive heart
failure (CHF) and conduction system abnormalities.
CHF in cardiac amyloidosis is most commonly diastolic in nature (heart failure
with preserved ejection fraction) with systolic dysfunction occurring late in disease
course. As a result, there is a distinct lack of therapies with demonstrated mortality
benefit. The cornerstone of treatment remains restricting salt and fluids in addition to
the judicious use of diuretics[2,12]. A combination of loop diuretics and aldosterone
receptor antagonist appears to work best although close monitoring of volume status
is  required as  CA patients  are  preload dependent[12,31].  Traditional  therapies  for
systolic  heart  failure  such  as  beta-blockers  and  angiotensin  converting  enzyme
inhibitors are avoided due to risks of hypotension and renal injury.
Atrial fibrillation is the most common arrhythmia encountered[19] and usual rate
controlling medications including beta blockers and calcium channel blockers are
poorly tolerated due to their hypotensive side effects. Digoxin is also best avoided due
to increased risk of toxicity from binding to the amyloid fibrils[32]. Amiodarone is a
commonly used option and is relatively well tolerated[9]. Cardiac amyloidosis patients
are at increased risk of intracardiac thrombus formation (especially AL) and this risk
is further exacerbated in setting of atrial fibrillation. Anticoagulation is thus indicated
with some centers recommending anticoagulation even in normal sinus rhythm if
atrial mechanical dysfunction is present[33].  Permanent pacemaker implantation is
indicated for symptomatic therapy in patients with higher degree heart blocks. There
is limited evidence for the mortality benefit of ICD in primary prevention as sudden
death most commonly occurs from bradycardia and pulseless electrical activity[34,35].
There are 2 main approaches to treating the underlying amyloidosis – stopping
further  production of  the precursor  protein and reducing the burden of  already
deposited amyloid.
In  AL,  therapy  is  directed  towards  the  plasma cell  clone  with  chemotherapy
followed by autologous hematopoietic  stem cell  transplant  (HSCT)[21].  The most
commonly  used  chemotherapy  regimen  involves  the  use  of  bortezomib,
dexamethasone and an alkylating agent – typically cyclophosphamide which has
demonstrated benefit in lower risk patients[6]. A significant proportion of patients with
AL have advanced cardiac disease at the time of diagnosis which limits their ability to
receive high dose chemotherapy and HSCT.
With  the  liver  being  the  primary  site  of  TTR  production,  orthotropic  liver
transplantation (OLT) has been used as a curative strategy for the treatment of mutant
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Figure 6
Figure 6  Doppler demonstrating restrictive physiology with lateral E’ velocity of 3.07cm/s and E/Lat E’ 35.5.
ATTR.  Although  this  brought  about  an  improvement  in  neurologic  symptoms,
Dubrey et al[36] noted a progression in ventricular thickening despite elimination of
TTR production. This has been hypothesized to be due to the deposition of wild type
TTR on the pre-existing focus of mutant TTR[37]. OLT is not validated in the treatment
of wild type ATTR.
Several interventions aimed at decreasing the production of TTR are at various
stages of development. In August 2018, the Food and Drug Administration (FDA)
approved patisiran for the treatment of polyneuropathy associated with mutant ATTR
after meeting the primary end point in the APOLLO clinical trial[38].  Patisiran is a
small interfering ribonucleic acid that targets the TTR messenger ribonucleic acid
(mRNA) and decreases gene expression[2,9].  On analysis of the APOLLO study by
Solomon et al[39], patisiran was also noted to decrease cardiac parameters such as the
mean LV wall  thickness and global longitudinal strain with improvement in CO
indicating a potential role in the treatment of ATTR cardiac amyloidosis.
In a similar vein, the anti-sense oligonucleotide inotersen was approved by the
FDA for the treatment of polyneuropathy associated with mutant ATTR in October
2018.  It  decreases  the  production of  TTR by binding the  mRNA and causing its
degradation[2]. Further studies on its effect on cardiac disease are needed.
An  alternative  approach  to  treating  ATTR  involves  the  use  of  TTR  tetramer
stabilizers (such as tafamidis) which bind at specific sites on the TTR molecule and
stabilize its  tetrameric structure preventing further amyloid fibril  formation[2].  A
recently  completed phase 3  trial  (ATTR-ACT trial)  demonstrated the benefits  of
tafamidis in ATTR cardiac amyloidosis with reductions in all-cause mortality and
cardiovascular related hospitalizations in both the mutant and wild-type disease[40].
Tafamidis has been designated a breakthrough therapy by the FDA and is currently
awaiting approval.
Diflunisal, a non-steroidal anti-inflammatory drug stabilizes the TTR molecule in a
similar  manner preventing amyloid fibrillogenesis.  It  demonstrated its  utility in
decreasing  the  rate  of  neurologic  deterioration  in  patients  with  neuropathic
manifestations of mutant ATTR[41]. Its use in advanced cardiac disease is however
limited by side effects such as fluid retention and renal insufficiency.
A third approach towards treatment of ATTR cardiac amyloidosis involves the use
of  agents  that  disrupt  and  facilitate  clearance  of  already  deposited  fibrils.  The
tetracycline antibiotic doxycycline in combination with tauroursodeoxycholic acid, a
biliary acid, has demonstrated some utility in this role in mouse models but human
studies are limited[42].
The role of orthotropic heart transplantation (OHT) in the management of cardiac
amyloidosis remains controversial due to concerns about recurrence of disease in
transplanted hearts and long-term patient survival in an era with limited donors[43]. It
however  may  be  the  only  treatment  option  for  many  patients.  In  AL  cardiac
amyloidosis,  patients  are  only  considered  for  transplant  if  they  have  limited
extracardiac  involvement  and  have  demonstrated  good  response  to  initial
chemotherapy (with expectation that the plasma cell clone can be controlled)[2,12]. In
ATTR cardiac amyloidosis, combined OHT and OLT may be considered in patients
without other comorbidities[9,43].
Prognosis
Despite advancements in the diagnosis and treatment of cardiac amyloidosis, the
overall prognosis remains poor. In untreated patients, ATTR cardiac amyloidosis has
a slowly progressive course and a better prognosis than AL cardiac amyloidosis. The
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Figure 7
Figure 7  Planar scintigraphy using 99Technetium pyrophosphate for detection of amyloid protein in the heart.
Quantitative analysis of heart retention (done 4 h after injection of 99Technetium pyrophosphate) showed a heart to
contralateral (H/CL) ratio of 1.8 (a ratio of > 1.5 is considered to strongly suggest ATTR amyloid deposition).
nature of the precursor protein (wild type vs mutant transthyretin) influences disease
progression and outcomes[44].  In wild type ATTR cardiac amyloidosis, the median
survival from the time of diagnosis is reported to be about 4 years with the primary
cause of death most commonly cardiovascular in nature[45,46]. Predictors of reduced
survival include advanced age, elevated BNP, decreased LVEF and increased relative
wall thickness[45,46]. In mutant ATTR cardiac amyloidosis, outcomes are dependent on
the nature of the underlying mutation. The Val122Ile mutation is associated with
worse outcomes with a median survival from diagnosis of about 2 years[47].
In untreated AL cardiac amyloidosis, median survival is about 6 months from the
onset of heart failure[48].  In patients with early stage disease who undergo HSCT,
reduced post-transplant mortality and improved survival has been demonstrated
with 4 year overall survival of about 90%[49,50].
CONCLUSION
Cardiac amyloidosis remains a rare disease despite a recent uptick in diagnoses owing
to increased physician suspicion and improved cardiovascular imaging techniques.
With emerging therapies that have the potential to improve patient outcomes, early
diagnosis has taken on an increasingly important role. This case report discusses the
clinical evaluation of cardiac amyloidosis highlighting the utility of various laboratory
tests and imaging modalities in arriving at a diagnosis.
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